Panel Discussion:Mapping the Therapeutic Target Landscape for B-Cell Mediated Autoimmune Disease & T-Cell Dependent Autoantibody Responses

Time: 9:30 am
day: Day One


  • Assessing the depletion of B-cells with anti-CD20 monoclonal antibodies
  • Exploring how to best target CD8 T suppressor cells
  • Discussing the various autoantigen specific B cell depleting and modulating therapies (CAART, BTK inhibitors, anti-CD20), targeting T-cell co-stimulatory pathways (CD40/CD40L, CD28/CTLA-4, OX40, ICOS, PD-1), and subduing autoantibody (FcRn inhibitors) approaches